An article this week in Politico entitled “Obamacare’s November Surprise” observes that premium announcements for Obamacare’s exchanges should be published around November 1, and that the news will be offputting, to say the least. Double digit increases from beleaguered insurers are likely, reflecting substantial structural and financial flaws within the exchanges as currently designed. The article suggests that this might be problematic for Democrats.
I’m doubtful whether, even if there is November rate shock, that it will substantially derail the then Democratic candidate, which absent some stunning intervening event will be Hillary Clinton. While the ACA is a natural extension of what Ms. Clinton has advocated for decades, she did not design the exchanges, and to hold her responsible for their design flaws seems a tad unfair. Likewise, she always has taken the position that rather than repeal the ACA, its flaws should be rectified. Easily said, a very safe position to take, and fair enough as it goes.
But what IS going on with the exchanges and the many co-ops that have failed? What happened?
It was the Mother of unintended consequences. 
As promised last week, I’ve read and taken detailed notes on the
Few appreciate the threat of antibiotic resistance to human medicine more than readers of this blog. You know antibiotics as lifesaving “miracle” drugs that treat sepsis, save victims of burns and trauma, and are crucial to survival of patients receiving transplants and cancer treatment.
Opinions about the U.S. health system vary widely based largely on our individual experiences as users from time to time. And most Americans don’t think of it as a system at all. Rather, it’s a collection of doctors, hospitals, insurers, drug and device manufacturers and others that operate in a complicated, disconnected, expensive industry that’s increasingly difficult to navigate and afford.